Paper Details

  1. Home
  2. Paper Details

A double-blind, multicentre comparison of intravenous dolasetron mesilate and metoclopramide in the prevention of nausea and vomiting in cancer patients receiving high-dose cisplatin chemotherapy.

Author: BastitP, CalsL, CappelaereP, CatimelG, ChevallierB, ClaverieN, FabbroM, GiovanniniM, KhayatD, SplinterT, WendlingJ L

Clinical TrialA clinical trial is a planned study conducted on humans to evaluate the efficacy and safety of pharmaceuticals, medical devices, and treatment methods. It aims to explore the possibilities of new treatments and improve the health of patients.
Comparative StudyResearch that compares multiple groups/interventions to determine differences/similarities in outcomes/characteristics.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Multicenter StudyResearch conducted in collaboration with multiple research institutions. It aims to collect a wide range of data and obtain more generalizable results.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Overview

Dolasetron mesilate was effective for the prevention of CINV with high-dose cisplatin. Single i.v. doses of dolasetron mesilate were more effective than 7 mg/kg metoclopramide in preventing nausea and vomiting induced by highly emetogenic cisplatin-containing chemotherapy.
Paper Details　
Original Abstract of the Article :
The potent serotonin receptor (5-HT3) antagonists are new highly selective agents for the prevention and control of chemotherapy-induced nausea and vomiting that have been shown to be comparable to or more effective than traditional metoclopramide regimens. This study was designed to compare the ant...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1007/BF01681958

データ提供：米国国立医学図書館（NLM）

Combatting Chemotherapy-Induced Nausea and Vomiting: Dolasetron vs. Metoclopramide

Chemotherapy, a vital weapon in the fight against cancer, often comes with unwelcome side effects, such as nausea and vomiting. This study explores the effectiveness of two antiemetic medications, dolasetron and metoclopramide, in preventing chemotherapy-induced nausea and vomiting (CINV). The researchers conducted a double-blind, randomized clinical trial comparing the efficacy and safety of these medications in patients receiving high-dose cisplatin chemotherapy. Their findings suggest that dolasetron is significantly more effective than metoclopramide in preventing CINV, offering a potentially better option for patients undergoing chemotherapy.

A Battle Against Nausea: Dolasetron Emerges as a Champion

This study provides valuable insights into the management of CINV, demonstrating the superior effectiveness of dolasetron over metoclopramide in preventing this debilitating side effect of chemotherapy. The researchers have successfully compared these two medications, offering a clear recommendation for clinicians seeking to improve patient comfort during chemotherapy.

Optimizing Chemotherapy: Improving Patient Comfort and Well-being

This research emphasizes the importance of effectively managing chemotherapy-related side effects to improve patient comfort and quality of life. The findings highlight the potential benefits of dolasetron in reducing CINV, offering a valuable tool for clinicians to optimize chemotherapy treatment and minimize the negative impact on patients.

Dr.Camel's Conclusion

This study provides a beacon of hope for patients undergoing chemotherapy, offering a potentially more effective medication for preventing CINV. The findings highlight the importance of choosing the right antiemetic medication to minimize chemotherapy side effects and improve patient comfort during treatment.

Date :
  1. Date Completed 1997-04-29
  2. Date Revised 2019-11-01
Further Info :

Pubmed ID

9010986

DOI: Digital Object Identifier

10.1007/BF01681958

Related Literature

Article Analysis
・Effects of dolasetron injection
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.